Cited by 119Alzheimer's disease research and treatmentsDementia and Cognitive Impairment ResearchCholinesterase and Neurodegenerative Diseases

The DOI matches its Crossref record; 248 of the 250 references it cites were found in a registry or an index.

Disease modifying therapy for AD?1

Open access

Golde, Todd E.·2006·Journal of Neurochemistry

DOI 10.1111/j.1471-4159.2006.04211.x

Open this paper in CoChat — free account Open PDF

Abstract

Alzheimer's disease (AD) is the most common form of dementia in industrialized nations. If more effective therapies are not developed that either prevent AD or block progression of the disease in its very early stages, the economic and societal cost of caring for AD patients will be devastating. Only two types of drugs are currently approved for the treatment of AD: inhibitors of acetyl cholinesterase, which symptomatically enhance cognitive state to some degree but are not disease modifying; and the adamantane derivative, memantine. Memantine preferentially blocks excessive NMDA receptor activity without disrupting normal receptor activity and is thought to be a neuroprotective agent that blocks excitotoxicty. Memantine therefore may have a potentially disease modifying effect in multiple neurodegenerative conditions. An improved understanding of the pathogeneses of AD has now led to the identification of numerous therapeutic targets designed to alter amyloid beta protein (Abeta) or tau accumulation. Therapies that alter Abeta and tau through these various targets are likely to have significant disease modifying effects. Many of these targets have been validated in proof of concept studies in preclinical animal models, and some potentially disease modifying therapies targeting Abeta or tau are being tested in the clinic. This review will highlight both the promise of and the obstacles to developing such disease modifying AD therapies.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1111/j.1471-4159.2006.04211.x

Cites

248 of 248 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Items 201–248 of 248

PKCε increases endothelin converting enzyme activity and reduces amyloid plaque pathology in transgenic mice
Choi, D., Wang, D., Yu, G.-Q., Zhu, G., Kharazia, V., Paredes, J. P., Chang, W. S., Deitchman, J. K., Mucke, L., & Messing, R. O. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0509725103 · Cited by 119
Modeling Tau Polymerization in Vitro: A Review and Synthesis
Gamblin, T. C., Berry, R. W., & Binder, L. I. (2003) · Biochemistry · doi:10.1021/bi035722s · Cited by 114
Tissue Plasminogen Activator Requires Plasminogen to Modulate Amyloid‐β Neurotoxicity and Deposition
Tucker, H. M., Kihiko‐Ehmann, M., Wright, S., Rydel, R. E., & Estus, S. (2000) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2000.0752172.x · Cited by 113
Insights into the mechanisms of action of anti‐Aβ antibodies in Alzheimer's disease mouse models
Levites, Y., Smithson, L. A., Price, R. W., Dakin, R. S., Yuan, B., Sierks, M. R., Kim, J., McGowan, E., Kim Reed, D., Rosenberry, T. L., et al. (2006) · The FASEB Journal · doi:10.1096/fj.06-6463fje · Cited by 113
Self-citation
Virus and virus-like particle-based immunogens for Alzheimer's disease induce antibody responses against amyloid-β without concomitant T cell responses
Chackerian, B., Rangel, M., Hunter, Z. N., & Peabody, D. S. (2006) · Vaccine · doi:10.1016/j.vaccine.2006.05.059 · Cited by 110
Stabilization of the Tau Exon 10 Stem Loop Alters Pre-mRNA Splicing
Donahue, C. P., Muratore, C., Wu, J. Y., Kosik, K. S., & Wolfe, M. S. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.c600143200 · Cited by 110
Neurovascular Pathways and Alzheimer Amyloid β-peptide
Zlokovic, B. V., Deane, R., Sallstrom, J., Chow, N., & Miano, J. M. (2006) · Brain Pathology · doi:10.1111/j.1750-3639.2005.tb00103.x · Cited by 104
Biochemical Identification of the Neutral Endopeptidase Family Member Responsible for the Catabolism of Amyloid Peptide in the Brain
Takaki, Y., Iwata, N., Tsubuki, S., Taniguchi, S., Toyoshima, S., Lu, B., Gerard, N. P., Gerard, C. J., Lee, H., Shirotani, K., et al. (2000) · The Journal of Biochemistry · doi:10.1093/oxfordjournals.jbchem.a022839 · Cited by 101
γ-Secretase Substrate Selectivity Can Be Modulated Directly via Interaction with a Nucleotide-binding Site
Fraering, P. C., Ye, W., LaVoie, M. J., Ostaszewski, B. L., Selkoe, D. J., & Wolfe, M. S. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m501368200 · Cited by 100
The Aβ Hypothesis: Leading Us to Rationally-Designed Therapeutic Strategies for the Treatment or Prevention of Alzheimer Disease
Golde, T. E. (2006) · Brain Pathology · doi:10.1111/j.1750-3639.2005.tb00104.x · Cited by 99
Self-citation
Molecular Genetics of Chromosome 17 Tauopathies
HUTTON, M. (2000) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2000.tb06906.x · Cited by 92
Number of A β Inoculations in APP+PS1 Transgenic Mice Influences Antibody Titers, Microglial Activation, and Congophilic Plaque Levels
Wilcock, D. M., Gordon, M. N., Ugen, K. E., Gottschall, P. E., DiCarlo, G., Dickey, C. A., Boyett, K. W., Jantzen, P. T., Connor, K. E., Melachrino, J., et al. (2001) · DNA and Cell Biology · doi:10.1089/10445490152717596 · Cited by 87
The inflammation-induced pathological chaperones ACT and apo-E are necessary catalysts of Alzheimer amyloid formation
Potter, H. (2001) · Neurobiology of Aging · doi:10.1016/s0197-4580(01)00308-6 · Cited by 87
The neuroprotective effects of Cerebrolysin? in a transgenic model of Alzheimer?s disease are associated with improved behavioral performance
Rockenstein, E. M., Adame, A., Mante, M., Moessler, H., Windisch, M., & Masliah, E. (2003) · Journal of Neural Transmission · doi:10.1007/s00702-003-0025-7 · Cited by 83
In Vivo Reversal of Amyloid-β Lesions in Rat Brain
Sigurdsson, E. M., Permanne, B., Soto, C. A., Wısnıewskı, T., & Frangione, B. (2000) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/59.1.11 · Cited by 83
Splicing of juvenile and adult tau mRNA variants is regulated by thyroid hormone.
Aniello, F., Couchie, D., Bridoux, A.-M., Gripois, D., & Nunez, J. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.9.4035 · Cited by 82
Inhibition of amyloid precursor protein processing by β-secretase through site-directed antibodies
Arbel, M., Yacoby, I., & Solomon, B. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0502427102 · Cited by 76
α‐Secretase Activity of the Disintegrin Metalloprotease ADAM 10: Influences of Domain Structure
Fahrenholz, F., GILBERT, S., Kojro, E., Lammich, S., & Postina, R. (2000) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2000.tb06925.x · Cited by 75
Alternate Aggregation Pathways of the Alzheimer β-Amyloid Peptide
Huang, T. H. J., Yang, D., Fraser, P. E., & Chakrabartty, A. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m005698200 · Cited by 74
From Acetylcholine to Amyloid: Neurotransmitters and the Pathology of Alzheimer's Disease
Nitsch, R. M. (1996) · Neurodegeneration · doi:10.1006/neur.1996.0066 · Cited by 71
Atorvastatin Therapy Lowers Circulating Cholesterol but not Free Radical Activity in Advance of Identifiable Clinical Benefit in the Treatment of Mild-to-Moderate AD
Sparks, D. L., Sabbagh, M., Connor, D. J., Lopez, J., Launer, L. J., Petanceska, S. S., Browne, P. J., Wassar, D., Johnson‐Traver, S., & Lochhead, J. J. (2005) · Current Alzheimer Research · doi:10.2174/1567205054367900 · Cited by 71
Inhibitors of TACE and Caspase-1 As Anti-inflammatory Drugs
Le, G. T., & Abbenante, G. (2005) · Current Medicinal Chemistry · doi:10.2174/092986705774462851 · Cited by 66
Elevated amyloid β protein (Aβ42) and late onset Alzheimer's disease are associated with single nucleotide polymorphisms in the urokinase-type plasminogen activator gene
Ertekin‐Taner, N., Ronald, J., Feuk, L., Prince, J. A., Tucker, M., Younkin, L. H., Hella, M., Jain, S., Hackett, A. M., Scanlin, L., et al. (2004) · Human Molecular Genetics · doi:10.1093/hmg/ddi041 · Cited by 66
Caspase-cleaved tau accumulation in neurodegenerative diseases associated with tau and α-synuclein pathology
Newman, J., Rissman, R. A., Sarsoza, F. M., Kim, R. C., Dick, M. B., Bennett, D. A., Cotman, C. W., Rohn, T. T., & Head, E. (2005) · Acta Neuropathologica · doi:10.1007/s00401-005-1027-3 · Cited by 55
Immunological and Anti-Chaperone Therapeutic Approaches for Alzheimer Disease
Wısnıewskı, T., & Frangione, B. (2006) · Brain Pathology · doi:10.1111/j.1750-3639.2005.tb00102.x · Cited by 54
The molecular genetics of the tauopathies
vanSlegtenhorst, M., LEWIS, J., & Hutton, M. L. (2000) · Experimental Gerontology · doi:10.1016/s0531-5565(00)00114-5 · Cited by 51
Translational Research on the Way to Effective Therapy for Alzheimer Disease
Rosenberg, R. N. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.11.1186 · Cited by 51
Amyloid Inhibitors and β-Sheet Breakers
Soto, C. A., & Estrada, L. D. (2006) · Springer eBooks · doi:10.1007/0-387-23226-5_18 · Cited by 47
Lithium Chloride Increases the Production of Amyloid-β Peptide Independently from Its Inhibition of Glycogen Synthase Kinase 3
Feyt, C., Kienlen‐Campard, P., Leroy, K., N’Kuli, F., Courtoy, P. J., Brion, J., & Octave, J. N. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m501610200 · Cited by 46
Regulation of tau RNA Maturation by Thyroid Hormone Is Mediated by the Neural RNA-Binding Protein Musashi-1
Cuadrado, A., García‐Fernández, L., Imai, T., Okano, H., & Múñoz, A. (2002) · Molecular and Cellular Neuroscience · doi:10.1006/mcne.2002.1131 · Cited by 43
Modulation of the humoral and cellular immune response in Aβ immunotherapy by the adjuvants monophosphoryl lipid A (MPL), cholera toxin B subunit (CTB) and E. coli enterotoxin LT(R192G)
Maier, M., Seabrook, T. J., & Lemere, C. A. (2005) · Vaccine · doi:10.1016/j.vaccine.2005.06.018 · Cited by 42
Anti‐amyloid activity of neprilysin in plaque‐bearing mouse models of Alzheimer's disease
Mohajeri, M. H., Kuehnle, K., Li, H., Poirier, R., Tracy, J., & Nitsch, R. M. (2004) · FEBS Letters · doi:10.1016/s0014-5793(04)00169-3 · Cited by 42
Constitutive overactivation of protein kinase C in guinea pig brain increases α‐secretory APP processing without decreasing β‐amyloid generation
Roßner, S., Beck, M., Stahl, T., Mendla, K. D., Schliebs, R., & Bigl, V. (2000) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2000.00211.x · Cited by 41
Plasmin deficiency does not alter endogenous murine amyloid beta levels in mice.
Tucker, H., Simpson, J., Kihiko‐Ehmann, M., Younkin, L., Mcgillis, J. P., Younkin, S., Degen, J., & Estus, S. (2004) · Neuroscience Letters · doi:10.1016/j.neulet.2004.07.011 · Cited by 40
Identification of Novel Small Molecule Inhibitors of Amyloid Precursor Protein Synthesis as a Route to Lower Alzheimer’s Disease Amyloid-β Peptide
Utsuki, T., Yu, Q.-S., Davidson, D., Chen, D., Holloway, H. W., Brossi, A. R., Sambamurti, K., Lahiri, D. K., Greig, N. H., & Giordano, T. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.103309 · Cited by 39
Physiologic and Pathologic Events Mediated by Intramembranous and Juxtamembranous Proteolysis
Golde, T. E., & Eckman, C. B. (2003) · Science Signaling · doi:10.1126/stke.2003.172.re4 · Cited by 36
Self-citation
Parkinson′s Disease: Clinical Signs and Symptoms,Neural Mechanisms, Positron Emission Tomography,and Therapeutic Interventions
Leenders, K. L., & Oertel, W. H. (2001) · Neural Plasticity · doi:10.1155/np.2001.99 · Cited by 34
Regulated cleavage of the Alzheimer amyloid precursor protein: Molecular and cellular basis
Gandy, S., & Greengard, P. (1994) · Biochimie · doi:10.1016/0300-9084(94)90162-7 · Cited by 30
Caspase-3-mediated cleavage of PHF-1 tau during apoptosis irrespective of excitotoxicity and oxidative stress: an implication to Alzheimer's disease
Kang, H. J., Yoon, W. J., Moon, G. J., Kim, D. Y., Sohn, S., Kwon, H. J., & Gwag, B. J. (2005) · Neurobiology of Disease · doi:10.1016/j.nbd.2004.12.004 · Cited by 27
Virosome-Based Active Immunization Targets Soluble Amyloid Species Rather Than Plaques in a Transgenic Mouse Model of Alzheimer's Disease
Zurbriggen, R., Amacker, M., Kammer, A. R., Westerfeld, N., Borghgraef, P., LEUVEN, F. V., der Auwera, I. V., & Wera, S. (2005) · Journal of Molecular Neuroscience · doi:10.1385/jmn:27:2:157 · Cited by 25
Apolipoprotein E4 as a Target for Developing New Therapeutics for Alzheimer's Disease
Refolo, L. M., & Fillit, H. M. (2004) · Journal of Molecular Neuroscience · doi:10.1385/jmn:23:3:151 · Cited by 20
Phorbol esters affect multiple steps in beta-amyloid precursor protein trafficking and amyloid beta-protein production.
Koo, E. H. (1997) · PubMed · Cited by 19
Phorbol Esters Affect Multiple Steps in β-Amyloid Precursor Protein Trafficking and Amyloid β-Protein Production
Koo, E. H., & Greengard, P. (1997) · Molecular Medicine · doi:10.1007/bf03401673 · Cited by 16
Cellular Models for Tau Filament Assembly
Ko, L., Deture, M. A., Sahara, N., Chihab, R., & Yen, S.-H. C. (2002) · Journal of Molecular Neuroscience · doi:10.1385/jmn:19:3:309 · Cited by 14
Open peer commentary regarding Aβ immunization and CNS inflammation by Pasinetti et al.
DAS, P., & Golde, T. E. (2002) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00031-3 · Cited by 10
Self-citation
Alpha 1-antichymotrypsin in brain aging and disease.
Abraham, C. R., & Potter, H. (1989) · PubMed · Cited by 9
Effects of Rofecoxib or Naproxen vs Placebo on Alzheimer Disease Progression: A Randomized Controlled Trial
Aisen, P. S., Schafer, K. A., Grundman, M., Pfeiffer, E., Sano, M., Davis, K. L., Farlow, M. R., Jin, S., Thomas, R. G., Thal, L. J., et al. (2003) · JAMA · doi:10.1001/jama.289.21.2819 · Cited by 5
Pgp deficiency increases amyloid concetrations in the brain
Thomas, L. L. (2005) · The Lancet Neurology · doi:10.1016/s1474-4422(05)70238-6 · Cited by 2

Flagged first, then by citations

2 of the 250 references couldn’t be matched to a known paper.

Research works printed but not linked: 2

Black S., 2006, Efficacy and safety ofMPC‐7869 (R.‐flurbiprofen), a selective Abeta42 loering agent in mild Alzheimer's disease: results of a 12‐month phase 2 trial and 1‐year follow on study, Neurology, 66, A347
Seabrook T. J., 2006, Dendrimeric Abeta1–15 is an effective immunogen in wildtype and APP‐tg mice, Neurobiol. Aging.

Sorted by citations

Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system - too little activation is bad, too much is even worse
Parsons, C. G., Stöffler, A., & Danysz, W. (2007) · Neuropharmacology · doi:10.1016/j.neuropharm.2007.07.013 · Cited by 724
Hyperphosphorylation of Microtubule-Associated Protein Tau: A Promising Therapeutic Target for Alzheimer Disease
Gong, C., & Iqbal, K. (2008) · Current Medicinal Chemistry · doi:10.2174/092986708785909111 · Cited by 672
Recent advances in the multitarget‐directed ligands approach for the treatment of Alzheimer's disease
Leon, R. M., García, A. G., & Marco, J. L. (2011) · Medicinal Research Reviews · doi:10.1002/med.20248 · Cited by 447
Common pathological processes in Alzheimer disease and type 2 diabetes: A review
Li, L., & Hölscher, C. (2007) · Brain Research Reviews · doi:10.1016/j.brainresrev.2007.09.001 · Cited by 367
Overexpression of Low-Density Lipoprotein Receptor in the Brain Markedly Inhibits Amyloid Deposition and Increases Extracellular Aβ Clearance
Kim, J., Castellano, J. M., Jiang, H., Basak, J. M., Parsadanian, M., Pham, V., Mason, S. M., Paul, S. M., & Holtzman, D. M. (2009) · Neuron · doi:10.1016/j.neuron.2009.11.013 · Cited by 274

See all 119

Authors: Golde, T. E.
Affiliations: Mayo Clinic (US)
Corresponding author: Golde, Todd E.
ORCID: Golde, Todd E.
Venue: Journal of Neurochemistry
Publisher: Wiley
Published: 2006-10-02
Volume: 99
Issue: 3
Pages: 689-707
ISSN: 0022-3042 (ISSN-L)
1471-4159
DOI: 10.1111/j.1471-4159.2006.04211.x
OpenAlex: W2056442085
Cited by: 117
References: 250
Citations by year: 2026: 2 · 2025: 4 · 2024: 3 · 2023: 2 · 2022: 2 · 2021: 2 · 2020: 2 · 2019: 2 · 2018: 1 · 2017: 3 · 2016: 5 · 2015: 3 · 2014: 3 · 2013: 5 · 2012: 6
FWCI: 2.06
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: onlinelibrary.wiley.com/termsAndConditions#vor (vor)
Locations: Journal of Neurochemistry (publishedVersion)
PubMed (publishedVersion)
Funders: Alzheimer's Association
National Institutes of Health
National Institute on Aging
Topics: Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
Keywords: Alzheimer's disease, disease-modifying therapy, amyloid-beta, tau protein, acetylcholinesterase inhibitors, memantine, NMDA receptor, neuroprotection, excitotoxicity, therapeutic target, clinical trials, dementia
MeSH terms: Alzheimer Disease, Animals, Humans, Immunotherapy, Peptide Hydrolases, Phosphorylation, Protease Inhibitors, Amyloid beta-Peptides, Neurofibrillary Tangles, tau Proteins, Protein Folding, Molecular Chaperones, Alzheimer Vaccines

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Disease modifying therapy for AD?1

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks